Full title: A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
Age: 18+
Phase: 3
Locations:
- London – Royal Marsden NHS Foundation Trust
- Manchester – The Christie NHS Foundation Trust
Brief summary:
This study is a phase 3 trial looking at whether the new drug, called IDRX-42, is effective in treating adults with Gastrointestinal Stromal Tumors (GIST) when compared to another drug named sunitinib. The study will see if IDRX-42 works well and is safe for participants whose GIST has spread or cannot be surgically removed, and who have already taken the drug imatinib.
More information can be found at clinicaltrials.gov
To find out more about this trial and whether you could take part, talk to your clinical team.
